Type 2 Diabetes Trial, Recruiting NCT07573917 Sponsor: Université de Sherbrooke Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT07573917
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to give written consent before any study procedures begin
  • Women who have been post-menopausal for at least 1 year (meaning at least 1 year since their periods stopped)
  • People aged between 40 and 75 years old
  • People with suitable veins for blood draws or having a needle inserted into a vein
  • People with a body mass index (BMI) between 25 and 38 (a measure of body weight relative to height)
  • People whose eating habits have been stable, with no weight change of more than 5 kg in the past 3 months
  • People who were diagnosed with type 2 diabetes at least 1.5 years before the study starts
  • People whose type 2 diabetes is reasonably well managed, with an HbA1c blood sugar level below 8.5% (a measure of average blood sugar over recent months)
  • People taking metformin alone, or metformin combined with certain other diabetes tablets (sulfonylureas and/or a DPP-IV inhibitor) at a stable dose for at least the past 3 months — people on a different diabetes medication called a GLP-1 agonist may be considered on a case-by-case basis (confirm with trial site)
  • People with no signs of active diabetes-related complications such as active heart or circulation problems, active diabetic foot, nerve damage, or eye disease
  • People with no signs of active liver or kidney problems

Who may not be able to join:

  • People who have taken part in another clinical trial involving an experimental treatment in the past 3 months, or as decided by the trial doctor
  • People who do moderate- to high-intensity sport or physical activity more than 3 times per week, or as decided by the trial doctor
  • People who have been regularly exposed to cold conditions in the month before the study starts — for example, through daily cold baths, working in a cold environment, or regular cold-water swimming or cold showers
  • People whose body weight has changed by more than 5 kg in the past 3 months
  • People who drink more than 2 alcoholic drinks per day (for men) or more than 1 alcoholic drink per day (for women)
  • People who smoke
  • People who use insulin or a type of diabetes medication called an SGLT2 inhibitor
  • People with heart failure or severe kidney or liver problems
  • People with low haemoglobin levels in the blood (below certain thresholds for men and women — confirm specific values with trial site)
  • People whose medical history, current medications, or fasting blood test results lead the trial doctor to advise that participation is not appropriate
  • People who are pregnant
  • People who have had a PET/CT scan as part of another study in the past year

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Denis P. Blondin, PhD, Université de Sherbrooke

Phone: 819-346-1110

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Université de Sherbrooke
Registry
ClinicalTrials.gov
Start date
24 September 2025
Est. completion
31 October 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Whole-body insulin sensitivity measured as glucose infusion rate (GIR) in µmol/kg/min during the stable period of the low- and high-insulin phase of the clamp.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov